Mycobacterium Drugs: Treatment of Multi-Drug Resistant Mycobacterial Infections

Case ID:
Web Published:

Researchers at Oregon Health & Science University and at the Portland VA Medical Center have discovered and are working to optimize a novel class of compounds for treatment of mycobacterium infections. The anti-mycobacterial agents are effective at inhibiting lipid transporter MmpL3, a highly conserved target amongst a variety of mycobacterium including M. smegmatis, M. tuberculosis, M. avium, M. avium paratuberculosis, M. bovis, M. bovis BCG, and M. leprae. If interested in learning more, please contact the Office of Technology Transfer and Business Development ( and reference Tech Id No. 2124. Investigator: Michael Riscoe, PhD and Georgiana Purdy, PhD.

Patent Information:
For Information, Contact:
Travis Cook
Senior Technology Development Manager
Oregon Health & Science University
Michael Riscoe
Georgiana Purdy
Marie Foss
Sovitj Pou
Rolf Winter
Rozalia Dodean
Therapeutics - Infectious Diseases
© 2018. All Rights Reserved. Powered by Inteum